Patent application reveals peptide triagonists targeting GIPR, GLP-1R, and GCGR, suggesting potential for diabetes treatment.
This patent application pertains to a novel class of peptide triagonists, generally represented by Formula I. These peptides exhibit selective activities toward GIPR (gastric inhibitory polypeptide receptor), GLP-1R (glucagon-like peptide-1 receptor), and GCGR (glucagon receptor). The unique pharma-cological profile of these triagonists offers promising therapeutic potential for the management of various conditions, including type 2 diabetes mellitus (T2DM), weight management, nonalcoholic fatty liver disease, etc.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: